Professor Ken Kato of the National Cancer Center Hospital Japan

"The Era of Enduring Severe Toxicity for Treatment Is Over"

Henryus, the global partner of Apclone, released an interview on June 15 with Professor Ken Kato of the National Cancer Center Hospital Japan, who is leading the global Phase 3 clinical trial (Pharos-001·HLX22-GC-301) of the HER2-positive gastric cancer treatment candidate HLX22.


Special interview video with Professor Ken Kato of the National Cancer Center Japan, posted on the official Henlius channel on the 13th. Abclone

Special interview video with Professor Ken Kato of the National Cancer Center Japan, posted on the official Henlius channel on the 13th. Abclone

View original image

In the interview, Professor Kato emphasized the importance of balancing efficacy and safety in cancer therapy, stating, "The era in which patients must endure severe toxicity to achieve efficacy is over."


He assessed that HLX22 shows the potential to improve both progression-free survival (PFS) and overall survival (OS) compared to existing standard treatments, while also demonstrating competitiveness in terms of toxicity.


In particular, he explained that while the competing drug zanidatamab showed a rate of grade 3 or higher severe diarrhea exceeding 20% in clinical trials, HLX22 exhibited a low incidence of diarrhea in previous clinical phases.



Professor Kato stressed that "if efficacy is similar, clinicians will choose the treatment with lower toxicity," highlighting the importance of treatment strategies that take into account patients' quality of life (QoL).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing